SEC Company Response from ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858) (ACHV) — Jun 9, 2017
ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858)
Date: June 9, 2017 · CIK: 0000949858 · Accession: 0001193125-17-199657
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-216961
Letter
ONCOGENEX PHARMACEUTICALS, INC.
19820 North Creek Parkway
Bothell, Washington 98011
June 9, 2017
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention:
Suzanne Hayes
Ada D. Sarmento
Erin Jaskot
Rolf Sundwall
Mark Brunhofer
Re:
OncoGenex Pharmaceuticals, Inc.
Registration Statement on Form S-4
File No. 333-216961
Originally filed March 27, 2017, as amended
Requested Date: June 13, 2017
Requested Time: 4:00 PM Eastern Time
Ladies and Gentlemen:
OncoGenex Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-4 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”).
The Registrant hereby authorizes Robert Freedman or Amanda Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553, or in her absence, Mr. Freedman at (650) 335-7292.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Sincerely,
ONCOGENEX PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ONCOGENEX PHARMACEUTICALS, INC. 19820 North Creek Parkway Bothell, Washington 98011 June 9, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Suzanne Hayes Ada D. Sarmento Erin Jaskot Rolf Sundwall Mark Brunhofer Re: OncoGenex Pharmaceuticals, Inc. Registration Statement on Form S-4 File No. 333-216961 Originally filed March 27, 2017, as amended Requested Date: June 13, 2017 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: OncoGenex Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-4 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes Robert Freedman or Amanda Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553, or in her absence, Mr. Freedman at (650) 335-7292. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] Sincerely, ONCOGENEX PHARMACEUTICALS, INC. By: /s/ John Bencich John Bencich Chief Financial Officer cc: Scott Cormack, Chief Executive Officer John Bencich, Chief Financial Officer OncoGenex Pharmaceuticals, Inc. Alan Smith, Esq. Robert Freedman, Esq. Kee Kim, Esq. Amanda Rose, Esq. Fenwick & West LLP Robert Carlson, Esq. Nicholas DeAngelis, Esq. Paul Hastings LLP